Navigation Links
Clinical Trial Demonstrates That EarlySense May Be An Effective Indicator for Respiratory Pattern Recognition
Date:1/13/2014

WALTHAM, Mass., Jan. 13, 2014 /PRNewswire/ -- EarlySense, the market leader in Proactive Patient Care Solutions, announced today the results of a small clinical trial conducted at Brigham and Women's Hospital in Boston that identifies complex respiratory patterns which were found to be correlated to patients' respiratory condition and have the potential to show when mechanical ventilation is no longer required.

"The study results show that unique, complex respiratory patterns have the potential to predict, on one hand, the patients' readiness to be separated from the ventilator, but, alternately, also the need for continued ventilatory support," said Dr. Gyorgy Frendl, MD, PhD, Director of Surgical Critical Care Research, Brigham and Women's Hospital, Assistant Professor of Anesthesia, Harvard Medical School, the Principal Investigator of the study. "For patients recently weaned from the ventilator, the appearance of these complex distress respiratory patterns indicated that they were likely to require further ventilator support:

  • Generalized disorganized respirations
  • Frequent [every 30-120 seconds] high amplitude gasping breaths
  • Periods of apnea >30 seconds

For ventilated patients, the above patterns indicated that the patient is not yet ready to be separated from the mechanical ventilator support.

"The ability to measure advanced respiratory patterns in a contact-free manner is a promising approach to improve care and keep patients safer," said Avner Halperin, CEO of EarlySense. We are honored that the EarlySense technology can determine respiratory patterns and provide clinicians with advanced tools to intervene effectively and, if required, early as evidenced in this study."

About EarlySense
EarlySense has brought to market an innovative technology designed to advance proactive patient care and empower clinicians to achieve better patient outcomes. Through early detection, the EarlySense system assists clinicians in identifying and preventing potential adverse events. It does so by providing motion rates and bed exit alarms, to help reduce falls and pressure ulcers, as well as surveillance of heart and respiratory rates to potentially detect patient deterioration. The company's flagship product, the EarlySense System, is a continuous, contact-free, patient safety monitoring solution that monitors and documents a patient's vital signs and movement using a sensor that is placed underneath a bed mattress. There are no leads or cuffs to connect to the patient who has complete freedom of movement and is not burdened by any cumbersome attachments. The system was designed to monitor patients on medical surgical floors who are usually monitored by nursing staff approximately once every four hours. The system is currently installed at hospitals and rehabilitation centers in the USA and Europe. It is also commercially available in Canada. Hospital administrators report that patients, their families and staff feel more comfortable knowing the system is in place. EarlySense Inc. is headquartered in Waltham, MA. 

Follow us on Twitter.
Like us on Facebook.


'/>"/>
SOURCE EarlySense
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CRLX101 Meets Primary Endpoint in Phase 2 Clinical Trial in Relapsed Ovarian Cancer
2. Seres Health Announces Interim Clinical Data for SER-109 in Recurrent C. difficile
3. Concordia Healthcare Corp. announces FDA agreement on Special Protocol Assessment for Phase 3 Clinical trial on new therapy to treat perihilar cholangiocarcinoma
4. EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA
5. arGEN-X Receives Two Preclinical Milestone Payments Under Collaboration With Shire
6. Kaiser Permanente-Led Team to Become Integral Part of New National Clinical Research Network
7. Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference
8. Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
9. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
10. Croissance Clinical Research Collaborates with Acceliant for Clinical Trial Excellence
11. BioSpecifics Technologies Corp. Announces Positive Top-line Data from Phase 2 Clinical Trial of CCH for the Treatment of Human Lipoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Allergy Diagnostics ... products and tests that are used to determine ... peanuts, milk, or drugs etc. in the samples ... the immune system. The report on global allergy ... of the market. The report consists of an ...
(Date:12/8/2016)... Connecticut , 8 de dezembro de 2016  A Mederi Therapeutics ... terapia Stretta, um tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). ... ... Live Stretta procedure performed and ... of Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... Dec. 8, 2016  Valeant Pharmaceuticals International, Inc. ... ("Valeant") today announced positive results from a Phase ... assess the safety and efficacy of IDP-118 (halobetasol ... plaque psoriasis. Within the Phase ... to severe psoriasis, IDP-118 showed statistical significance to ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical Center ... NY, on December 3rd, to benefit Holy Name Medical Center's programs and services. ... raised over $1 million - the largest event in the Center's history, both ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... Pennsylvania Cable Network (PCN) during the summer of 2016. The program was made ... by the United States Department of Health and Human Services Administration. The ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking attendance at ... for its 33rd Annual Issues & Research Conference, March 2-3, 2017, at ... the conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... a Property owned by an affiliate of Seavest, has won a prestigious national ... Southern Chester County ambulatory care center (ACC) was named “Best New Development, MOBs ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental ... Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related ... and prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 ...
Breaking Medicine News(10 mins):